News and Announcements
Cre8tek (ASX: CR8) Crosses a Major Milestone in its Agreement with US-Based Fortune 100 Insurance Firm Nationwide
- Published June 26, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Cre8tek Limited (ASX: CR8), owner of high-tech, Artificial Intelligence company and Cognitive Virtual Assistant platform provider, Flamingo Customer Experience Inc. (“Flamingo”), is pleased to provide the market with an update on the significant progress made with US-based client, Fortune 100 insurance firm, Nationwide.
KEY TAKEAWAYS:
- Extended Security Review approved by Fortune 100 company, Nationwide
- Flamingo Platform Architecture Review approved by Nationwide
- Flamingo progressing to integration and production phases of deployment
- Nationwide happy with progress
Cre8tek is pleased to announce Flamingo has received approval from Nationwide on the completion of the ‘non-negotiable’ extended security requirements, a very significant milestone in the Nationwide implementation, meaning that progress can now be made to integration and production. Nationwide will provide compensation for the work Flamingo has conducted in achieving this high security standard.
Nationwide Innovation Lead, Scott Bair, stated:
“Our partnership with Flamingo has been incredibly fruitful. We are happy to see the progress of the work with the Flamingo Cognitive Virtual Assistant platform and are looking forward to having it move into production in support of our new product. We’re excited about the potential of the platform and its Virtual Assistant capabilities, and will actively work with the Flamingo team to explore other use case scenarios across the Nationwide business”.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
